标题
Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-07-13
DOI
10.3389/fimmu.2022.940674
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
- (2021) Jason J Luke et al. Journal for ImmunoTherapy of Cancer
- Designed proteins assemble antibodies into modular nanocages
- (2021) Robby Divine et al. SCIENCE
- Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer
- (2021) Christopher S. Garris et al. Science Translational Medicine
- Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy
- (2021) Marie Siwicki et al. Science Immunology
- Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity
- (2020) Xiaojie Yu et al. CANCER CELL
- CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
- (2020) Caroline Bonnans et al. Journal for ImmunoTherapy of Cancer
- cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity
- (2020) Stephen T. Ferris et al. NATURE
- CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
- (2020) Mark H O'Hara et al. LANCET ONCOLOGY
- First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
- (2019) Sandra M. M. Irenaeus et al. INTERNATIONAL JOURNAL OF CANCER
- A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
- (2019) Joanie Del Bano et al. Frontiers in Immunology
- CD40 Agonist Antibodies in Cancer Immunotherapy
- (2019) Robert H. Vonderheide Annual Review of Medicine
- A BISPECIFIC MOLECULE TARGETING CD40 AND TUMOR ANTIGEN MESOTHELIN ENHANCES TUMOR-SPECIFIC IMMUNITY
- (2019) Shiming Ye et al. Cancer Immunology Research
- Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility
- (2019) Xiaobo Liu et al. Nature Communications
- The Immune Revolution: A Case for Priming, Not Checkpoint
- (2018) Robert H. Vonderheide CANCER CELL
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
- (2018) David A. Knorr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
- (2017) Andrew W Hahn et al. Immunotherapy
- A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.
- (2017) P. W. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
- (2016) Rony Dahan et al. CANCER CELL
- Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
- (2016) Nadia M. Luheshi et al. Oncotarget
- CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
- (2016) Katelyn T. Byrne et al. Cell Reports
- Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
- (2015) Ann L. White et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
- (2015) P. Johnson et al. CLINICAL CANCER RESEARCH
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- A Short History of the B-Cell-Associated Surface Molecule CD40
- (2014) Edward A. Clark Frontiers in Immunology
- CD40 immunotherapy for pancreatic cancer
- (2013) Robert H. Vonderheide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Antitumor activities of agonistic anti-TNFR antibodies require differential Fc RIIB coengagement in vivo
- (2013) F. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
- (2013) F. Chowdhury et al. Cancer Immunology Research
- Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
- (2013) L. C. Sandin et al. Cancer Immunology Research
- Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
- (2013) Robert H. Vonderheide et al. OncoImmunology
- Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
- (2011) Jens Rüter et al. CANCER BIOLOGY & THERAPY
- Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
- (2011) M. F. Fransen et al. CLINICAL CANCER RESEARCH
- Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
- (2011) A. L. White et al. JOURNAL OF IMMUNOLOGY
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started